G 蛋白偶联胆汁酸受体 1 (GPCR19、TGR5、GPBAR1) 是一种质膜结合的 G 蛋白偶联受体,其配体为胆汁酸。GPCR19 是能量稳态、胆汁酸稳态以及葡萄糖代谢的调节剂。GPCR19 通过异三聚体 G 蛋白传递细胞外信号。
GPCR19 可被胆汁酸激活,然后诱导 cAMP 产生。作为膜受体,GPCR19 可响应其配体内化到细胞质中。GPCR19 在细胞信号通路中起重要作用,例如核因子 κB (NF-κB)、AKT 和细胞外信号调节激酶 (ERK)。其激动剂可能是治疗代谢、炎症和消化系统疾病的潜在药物。此外,GPCR19 刺激胰高血糖素样肽 1 (GLP-1) 分泌。它也已成为预防和/或治疗肥胖症及其高度相关的 II 型糖尿病和代谢综合征的一个有吸引力的治疗目标。
G protein-coupled bile acid receptor 1 (GPCR19, TGR5, GPBAR1) is a plasma membrane-bound, G protein-coupled receptor that has bile acids as its ligand. GPCR19 is a regulator of energy homeostasis, bile acid homeostasis as well as glucose metabolism. GPCR19 transduces extracellular signals through heterotrimeric G proteins.
GPCR19 can be activated by bile acids and then it induces cAMP production. As a membrane receptor, GPCR19 can be internalized into the cytoplasm in response to its ligands. GPCR19 plays important roles in cell signaling pathways such as nuclear factor κB (NF-κB), AKT, and extracellular signal-regulated kinases (ERK). Its agonists may be potential drugs for the treatment of metabolic, inflammation, and digestive disorders. In addition, GPCR19 stimulates glucagon-like peptide 1 (GLP-1) secretion. It also has become an attractive therapeutic target for the prevention and/or the treatment of obesity and its highly associated Type II diabetes and metabolic syndrome.
SCH-202676 是一种 G 蛋白偶联受体 (GPCRs) 和腺苷受体 (adenosine receptor (AR)) 调节剂,具有抗流感活性,能以时间依赖的方式抑制 3CLpro,IC50 为 0.655 µM。
SSTR5/TGR5-modulator-1 是一种口服有效的双靶点小分子,可分别激活胆汁酸受体 TGR5 并拮抗生长抑素受体 SSTR5,通过激活 TGR5 促进 cAMP 积累、通过阻断 SSTR5 抑制激动剂诱导的钙动员,在改善小鼠葡萄糖耐量的同时能在药理学相关剂量下缓解胆囊充盈,显示出良好的体内药效,可用于 2 型糖尿病的相关研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号